Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

PHASE3CompletedINTERVENTIONAL

Enrollment

465

Participants

Timeline

Start Date

November 27, 2020

Primary Completion Date

May 18, 2021

Study Completion Date

May 18, 2021

Conditions

Functional Bowel Disorder

Interventions

DRUG

Mebeverine+Simethicone

fixed-dose combination, film-coated tablets, 135 mg + 80 mg

DRUG

Mebeverine

Duspatalin®, coated tablets 135 mg

DRUG

Simethicone

Espumisan® capsules 40 mg

Trial Locations (1)

Null Research Facilities, Moscow